Benralizumab Prefilled Syringe

ApprovedRecruiting
0 watching 0 views this week๐Ÿ”ฅ Hot
85
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
โœ“
Phase 3
5
Approved
Indication / Disease

Asthma; Eosinophilic

Conditions

Asthma; Eosinophilic, Severe Asthma

Trial Timeline

Oct 11, 2021 โ†’ Nov 1, 2026

About Benralizumab Prefilled Syringe

Benralizumab Prefilled Syringe is a approved stage product being developed by AstraZeneca for Asthma; Eosinophilic. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04565483. Target conditions include Asthma; Eosinophilic, Severe Asthma.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT04565483ApprovedRecruiting